Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 255

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis

Open access
Dagnew, Alemnew F, Ilhan, Osman, Lee, Won-Sik, Woszczyk, Dariusz, Kwak, Jae-Yong, Bowcock, Stella, Sohn, Sang Kyun, Rodriguez Macías, Gabriela, Chiou, Tzeon-Jye, Quiel, Dimas, Aoun, Mickael, Navarro Matilla, Maria Belen, de la Serna, Javier, Milliken, Samuel, Murphy, John, McNeil, Shelly A, Salaun, Bruno, Di Paolo, Emmanuel, Campora, Laura, López-Fauqued, Marta, El Idrissi, Mohamed, Schuind, Anne, Heineman, Thomas C, Van den Steen, Peter, Oostvogels, Lidia, Acar, Kadir, Afanasyev, Boris, Alonso Alonso, Aránzazu, Anttila, Veli-Jukka, Barba Suñol, Pere, Blesing, Norbert, Comeau, Terrance, del Campo, Teresa, Disperati, Patricia, Eek, Richard, Eom, HyeonSeok, Gaidano, Gianluca, Grosicki, Sebastian, Guillaume, Thierry, Homenda, Wojciech, Hwang, William, Ilyin, Nikolay, Johnston, Anna, Kim, Seok Jin, Kuo, Ching-Yuan, Kuvshinov, Aleksey, Lee, Dong-Gun, Lee, Jae Hoon, Lee, Je-Jung, Lepretre, Stephane, Lie, Albert Kwok-Wai, Lucchesi, Alessandro, Masood, Ahmed, Mir, Naheed, Miranda Castillo, Anna Carolina, Mullane, Kathleen, Myasnikov, Alexandr, Oña Navarrete, Raquel, Pauksens, Karlis, Peniket, Andrew, Perez de Oteyza, Jaime, Pohlreich, David, Pullon, Humphrey, Quittet, Philippe, Rodon, Philippe, Rombo, Lars, Samoylova, Olga, Sanmartin Berglund, Johan, Schattner, Ariah, Selleslag, Dominik, Sinisalo, Marjatta, Sultan, Faisal, Theunissen, Koen, Turner, Paul, Wang, Po-Nan, Yáñez San Segundo, Lucrecia, Young, Jo-Anne, Zachee, Pierre, Zaja, Francesco·2019·The Lancet Infectious Diseases

Abstract

BACKGROUND The adjuvanted recombinant zoster vaccine (Shingrix) can prevent herpes zoster in older adults and autologous haemopoietic stem cell transplant recipients. We evaluated the safety and immunogenicity of this vaccine in adults with haematological malignancies receiving immunosuppressive cancer treatments. METHODS In this phase 3, randomised, observer-blind, placebo-controlled study, done at 77 centres worldwide, we randomly assigned (1:1) patients with haematological malignancies aged 18 years and older to receive two doses of the adjuvanted recombinant zoster vaccine or placebo 1-2 months apart during or after immunosuppressive cancer treatments, and stratified participants according to their underlying diseases. The co-primary objectives of the study were the evaluation of safety and reactogenicity of the adjuvanted recombinant zoster vaccine compared with placebo from the first vaccination up to 30 days after last vaccination in all participants; evaluation of the proportion of participants with a vaccine response in terms of anti-glycoprotein E humoral immune response to the adjuvanted recombinant zoster vaccine at month 2 in all participants, excluding those with non-Hodgkin B-cell lymphoma and chronic lymphocytic leukaemia; and evaluation of the anti-glycoprotein E humoral immune responses to the vaccine compared with placebo at month 2 in all participants, excluding those with non-Hodgkin B-cell lymphoma and chronic lymphocytic leukaemia. We assessed immunogenicity in the per-protocol cohort for immunogenicity and safety in the total vaccinated cohort. The study is registered with ClinicalTrials.gov, number NCT01767467, and with the EU Clinical Trials Register, number 2012-003438-18. FINDINGS Between March 1, 2013, and Sept 10, 2015, we randomly assigned 286 participants to adjuvanted recombinant zoster vaccine and 283 to placebo. 283 in the vaccine group and 279 in the placebo group were vaccinated. At month 2, 119 (80·4%, 95% CI 73·1-86·5) of 148 participants had a humoral vaccine response to adjuvanted recombinant zoster vaccine, compared with one (0·8%, 0·0-4·2) of 130 participants in the placebo group, and the adjusted geometric mean anti-glycoprotein E antibody concentration was 23 132·9 mIU/mL (95% CI 16 642·8-32 153·9) in the vaccine group and 777·6 mIU/mL (702·8-860·3) in the placebo group (adjusted geometric mean ratio 29·75, 21·09-41·96; p<0·0001) in all patients, excluding those with non-Hodgkin B-cell lymphoma and chronic lymphocytic leukaemia. Humoral and cell-mediated immune responses persisted above baseline until month 13 in all strata and, as expected, vaccine was more reactogenic than placebo (within 7 days after vaccination pain was reported by 221 [79·5%] of 278 vaccine group participants and 45 [16·4%] of 274 placebo group participants; fatigue was reported by 162 [58·3%] of 278 vaccine group participants and 102 [37·2%] of 274 placebo group participants). Incidences of unsolicited or serious adverse events, potential immune-mediated diseases, disease-related events, and fatal serious adverse events were similar between the groups. INTERPRETATION The immunocompromised adult population with haematological malignancies is at high risk for herpes zoster. The adjuvanted recombinant zoster vaccine, which is currently licensed in certain countries for adults aged 50 years and older, is likely to benefit this population. FUNDING GlaxoSmithKline Biologicals SA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1473-3099(19)30163-x

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 255

Metadata

Authors
Dagnew, A. F., Ilhan, O., Lee, W.-S., Woszczyk, D., Kwak, J.-Y., Bowcock, S., Sohn, S. K., Rodriguez Macías, G., Chiou, T.-J., Quiel, D., Aoun, M., Navarro Matilla, M. B., de la Serna, J., Milliken, S., Murphy, J., McNeil, S. A., Salaun, B., Di Paolo, E., Campora, L., López-Fauqued, M., El Idrissi, M., Schuind, A., Heineman, T. C., Van den Steen, P., Oostvogels, L., Acar, K., Afanasyev, B., Alonso Alonso, A., Anttila, V.-J., Barba Suñol, P., Blesing, N., Comeau, T., del Campo, T., Disperati, P., Eek, R., Eom, H., Gaidano, G., Grosicki, S., Guillaume, T., Homenda, W., Hwang, W., Ilyin, N., Johnston, A., Kim, S. J., Kuo, C.-Y., Kuvshinov, A., Lee, D.-G., Lee, J. H., Lee, J.-J., Lepretre, S., Lie, A. K.-W., Lucchesi, A., Masood, A., Mir, N., Miranda Castillo, A. C., Mullane, K., Myasnikov, A., Oña Navarrete, R., Pauksens, K., Peniket, A., Perez de Oteyza, J., Pohlreich, D., Pullon, H., Quittet, P., Rodon, P., Rombo, L., Samoylova, O., Sanmartin Berglund, J., Schattner, A., Selleslag, D., Sinisalo, M., Sultan, F., Theunissen, K., Turner, P., Wang, P.-N., Yáñez San Segundo, L., Young, J.-A., Zachee, P., & Zaja, F.
Venue
The Lancet Infectious Diseases
Publisher
Elsevier BV
Published
2019-09
Volume
19
Issue
9
Pages
988-1000
ISSN
1473-3099 (ISSN-L)
OpenAlex
W2965743944
Cited by
255
References
32
FWCI
17.39
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. https://app.cochat.ai/papers/10.1016/s1473-3099(19)30163-x
The paper
Dagnew, A. F., Ilhan, O., Lee, W.-S., Woszczyk, D., Kwak, J.-Y., Bowcock, S., Sohn, S. K., Rodriguez Macías, G., Chiou, T.-J., Quiel, D., Aoun, M., Navarro Matilla, M. B., de la Serna, J., Milliken, S., Murphy, J., McNeil, S. A., Salaun, B., Di Paolo, E., Campora, L., . . . Zaja, F. (2019). Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(19)30163-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.